Management of Uterine Leiomyoma by Malik, Sobia Nawaz
Journal of Rawalpindi Medical College (JRMC); 2012;16(2):168-170 
 
 168 
Original Article  
Management of Uterine Leiomyoma 
 
Sobia Nawaz Malik,  Jehan Ara, Maliha Sadaf 
Department of Obstetrics/ Gynaecology District Head Quarters  Teaching Hospital and Rawalpindi Medical College, 
Rawalpindi 
 
 
Abstract 
 
Background : To determine the prevalence of 
clinically significant myomas and review various 
treatment options of uterine leiomyomas. 
Methods: In this cross-sectional study patients 
admitted for abnormal uterine bleeding, due to fibroids, 
were included in the study. It  included 54 premenopausal 
women, 30–50 years old, who had an intact uterus and 
were neither  pregnant nor lactating, or using oral 
contraception or intra-uterine devices.   
Results: Uterine leiomyomata were detected in 54 
women (22.4%) out of 240 patients admitted in the ward 
with abnormal uterine bleeding. Mean age for the women 
having leiomyoma was 39.3 years.Most women(18.4%) 
were multigravida. Surgical treatment was common 
treatment modality(70.3%) as compared to medical 
treatment(29.7%).  
Conclusion: Surgery continues to remain an important 
alternative when medical treatment fails to relieve  
symptoms of leiomyoma. 
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Introduction 
      Fibroids are the commonest tumour occurring in 
20% of all women of reproductive age. They are 
composed of smooth muscle with variable amount of 
connective tissue. Uterine fibroids which eventually 
develop in more than 50% of women, are 
asymptomatic but they can cause a range of symptoms 
and complications that challenge clinicians. They can 
complicate the pregnancy, mask the diagnosis of 
ovarian tumours and confuse the management of 
menopause by causing abnormal uterine bleeding.  
The prevalence of clinically significant myomas is at its 
peak in the perimenopausal years and declines after 
the menopause.  It is not known why some fibroids are 
symptomatic while others are quiescent. The size, 
number and location of fibroids undoubtedly 
determine their clinical behaviour.1,2  
   Recent developments in fibroids, including 
measurement of tissue receptor for steroids and 
growth factors, non-invasive methods of monitoring 
fibroid growth and the use of LHRH agonists have 
enabled study of the nature and response to therapy 
although much work remains to be 
done. Symptomatic fibroids require treatment. 
Effective  surgical options available are hysterectomy 
and myomectomy, and as yet there are no proven 
effective long-term medical therapies. Hysterectomy is 
the second most frequent major surgical procedure 
performed in women in the United States, second only 
to cesarean delivery. Twenty percent of women will 
have had a hysterectomy by the age of 40 and one 
third by age 65. Hysterectomy for fibroids is 
performed in 33.5%. Hysterectomy is  also the 
procedure of choice whenever there is a likelihood of 
malignancy within a myoma.3 
     Fortunately, the past decade has witnessed the 
emergence of highly sophisticated diagnostic and 
therapeutic technologies for fibroids. Magnetic 
resonance imaging and high-resolution ultrasound are 
non-invasive, high-quality diagnostic procedures. The 
new treatment modalities include: laparoscopic and 
vaginal myomectomy; uterine artery embolization 
(UAE); magnetic-resonance-guided focused 
ultrasound surgery (MRgFUS); hysteroscopic resection 
where the fibroids are submucous; myolysis by heat, 
cold coagulation and laser; laparoscopic uterine artery 
occlusion; and temporary transvaginal uterine artery 
occlusion. Laparoscopic surgery requires skills that are 
not common place, and there are limitations on the 
size and number of fibroids that can be treated by this 
modality. Much the same applies to vaginal 
myomectomy.UAE has a range of complications 
including premature ovarian failure, chronic vaginal 
discharge and pelvic sepsis, and may have limited 
efficacy when the fibroids are large.  MRgFUS was 
approved by the US Food and Drug Administration in 
2004, while NICE recommended that the procedure 
should be used in an audit and research setting.3,4  
 
Patients and Methods 
   This cross-sectional study, performed  from Nov2009 
to Oct 2011, in the Department of Obs & Gynaecology 
DHQ Teaching hospital, Rawalpindi, included 
premenopausal women, 30–50 years old, having 
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fibroid with an intact uterus and who were neither 
pregnant nor lactating, or using oral contraception or 
intra-uterine devices. Various treatments of 
leiomyoma were  examined and analysed. Based on 
the ultrasound examination size,tissue location, axial 
position and treatment received (medical and/or 
surgical) was recorded.  
 
Results 
    Out of 54 cases of fibroid uterus, 6 patients (37.50%) 
were treated with progesterone tablets in the form of 
primolut-N. Five patients (31.2%) were given 
antifibrinolytic agents,  danazole was prescribed only 
in 18.75%(Table-1).Mirena was given to only 2 
patients(12.50%).  Out of 16(29.63%) patients, 7 
(53.85%) noticed significant reduction in blood loss 
and they were willing to continue the same treatment. 
Medical treatment failed to reduce the menstrual 
blood loss in 7 patients (43.75%) and these patients 
were then treated surgically(Table 2).  Out of 45 
patients, treated surgically, 41 (91.1%) had undergone 
hysterectomy due to severity of symptoms and they 
had completed their family. Myomectomy was done in 
04(8.8%) patients (Table-3). Out of 34 patients in which 
hysterectomy was done, bilateral salpingo-
oophorectomy(BSO) was performed in 8 (23.53%) 
patients. In 7 (20.58%) patients unilateral salpingo-
oophorectomy (USO)was done and in 19 (55.89%) of 
patients only total abdominal hysterectomy(TAH) was 
performed (Table-4).  
 
Table 1:Medical treatment (n=16) 
  Medicines given No(%) 
Progesterone 6 (37.50%) 
Antifibrinolytics & NSAIDs 5 (31.20%) 
Danazole 3 (18.75%) 
Mirena* 2 (12.50%) 
*Mirena is an intrauterine progesterone releasing intrauterine 
system 
 
Table2:Response of medical treatment (n=16) 
 No (%) 
Medical treatment continued   9 (56.25) 
Failure of medical treatment 7(43.75%) 
 
Table 3: Surgical treatment 
n=4 + 41 (Patients with failed medical treatment)=45   
Type of surgery No (%) 
Myomectomy 04 (8.8) 
Hysterectomy 41(81.1) 
Table 4: Hysterectomy with or without 
salpingo-oophorectomy (n=34) 
Operation No(%) 
TAH 19 (55.89) 
TAH + BSO 08 (23.53) 
TAH + USO 07(20.58) 
 
Discussion 
     Hysterectomy is the second most frequent major 
surgical procedure performed in women in the United 
States, second only to caesarean delivery. Twenty 
percent of women will have had a hysterectomy by the 
age of 40, and one third by age 65. Indications for 
hysterectomy include uterine myomas (33.5%), 
endometriosis (18.2%), uterine prolapse (16.2%), and 
cancer (11.2%).      Removal of the uterus has been the 
usual procedure of choice whenever surgery is 
indicated for uterine myomas and when childbearing 
considerations have been fulfilled. Specific exceptions 
include a solitary subserous or pedunculated myoma 
and a submucous myoma readily accessible for 
hysteroscopic removal. 5 
     Common procedures such as hysterectomy and 
myomectomy, including choice among types of 
myomectomy, still cannot be meaningfully compared. 
Studies comparing uterine artery embolization (UAE) 
with other procedures reported procedure time and 
length of stay favoring UAE, but inconsistency of the 
direction of effect for complications and absence of key 
information on longer-term outcomes suggest that the 
evidence is inadequate to comment on the relative 
risks and benefits of UAE versus hysterectomy or 
myomectomy6.  
     In present study, success rate of progestogens in 
treating the menorrhagia was 42.86%. similar to a 
study done in Multan. There was significant reduction 
in menstrual blood in one patient, who was prescribed 
Danazole in our study, showing Danazole was 
effective in reducing blood loss  in menorrhagic 
patients with fibroid. In a placebo-controlled study 
administering 2.5 mg gestrinone (which is synthetic 
derivative of 19-nortestosterone) weekly for 12 weeks 
to 19 women with objectively diagnosed menorrhagia 
with fibroid, a marked reduction in menstrual blood 
loss was seen in 5 women, and 10 became 
amenorrhoeic.6 Three  (42.8%) patients out of five 
patients noticed significant improvement in 
menorrhagia with tranexamic acid in present study.No 
patient was prescribed GnRH analogue because 
almost all patients were poor and they could not 
afford such treatment.  
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     In present study, surgical treatment was given to 38 
patients as first option and in 7 patients after failed 
medical management. Out of 45 patients who 
underwent surgical treatment for fibroid associated 
menorrhagia, abdominal  hysterectomy was done in 41 
patients. Hysterectomy rate in present study was 
91.1%. No vaginal hysterectomy was done.  In another 
study, total hysterectomy rate was 69.4%, out of which 
abdominal hysterectomy was done in 66% of patients 
and in 3.4% of patients vaginal hysterectomy was done 
because uterine size was less than 12 weeks.7 
     Medical treatment of fibroids with GnRH analogues 
has been introduced since a long time, it does give a 
short term relief but regrowth occurs after cessation of 
treatment. Medical treatment does have some place in 
the management of perimenopausal women with 
myomas who want to avoid surgery in the hope that 
their disease will regress spontaneously with 
menopause. GnRH analogues are also in use as 
preoperative medication before myomectomy or 
hysterectomy to reduce operative morbidity. But non-
availability of analogues and their substantial cost has 
limited their use in Pakistan. Interventional 
radiologists should be aware of the clinical indications 
and potential risks for individual patients. 
Improvement of the procedure should include 
development of specific angiographic devices, use of 
an adapted embolic particle and training of 
interventional radiologists. 8 
 
Conclusions 
 1.Fibroid is one of important cause of menorrhagia in 
young patients with low parity but nullipara and 
multipara are not spared.  
2.Myomectomy is being performed increasingly for 
the treatment of fibroids in the patients who have not 
completed their families.  
3.Hysterectomy is definitive treatment of fibroid and  
is an effective treatment for fibroid associated 
menorrhagia.  
4. With advancement in field of diagnosis and 
management there is a lot of room for improvement  
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